News & Announcements
-
Orphan Drug Designation Status
/**/ RNS Number : 3886R IQ-AI Limited 28 February 2023 IQ-AI Announces Orphan Drug Designation Status FDA grants orphan status to Gallium Maltolate for treating GBM IQ-AI Limited, (LSE: IQAI) (OTCQB: IQAIF), is pleased to announce that the United States Food and Drug Administration (FDA) has granted orphan drug designation (ODD) status for gallium
-
Letter to Shareholders
/**/ RNS Number : 1496M IQ-AI Limited 10 January 2023 IQ-AI LIMITED ISSUES LETTER TO SHAREHOLDERS IQ-AI Limited (“IQAI”) (LSE: IQAI) (OTCQB: IQAIF) a developer and manufacturer of medical image processing platforms, has today released a letter to shareholders on behalf of Michael Schmainda, CEO of IQ-AI’s wholly-owned subsidiary Imaging Biometrics (the “Company”), covering several material
-
Holding in Company
/**/ RNS Number : 4535I IQ-AI Limited 02 December 2022 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to
-
Letter to Shareholders
/**/ RNS Number : 2244B IQ-AI Limited 30 September 2022 IQ-AI LIMITED ISSUES LETTER TO SHAREHOLDERS Imaging Biometrics, a subsidiary of IQ-AI Limited (OTCQB: IQAIF: LSE: IQAI), summarises the Company’s achievements in 2022 to date, which includes: · Company focuses on deployment of IB Clinic™ · IB NIMBLE™ connects experts to help treat
-
Issue of Warrants to Employees
/**/ RNS Number : 5398A IQ-AI Limited 26 September 2022 26 September 2022 IQ-AI Limited (“IQ-AI” or the “Company”) Issue of Warrants to Employees IQAI Limited (the “Company” or “IQAI”), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), which is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients